

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
)	
Kazuo UMEZAWA et al.)	
)	Group Art Unit: Not Yet Assigned
Application No.: Not Yet Assigned)	
)	Examiner: Not Yet Assigned
Filed: February 6, 2006)	
)	
National Stage of International Application)	
No. PCT/JP2004/011260 under 35 U.S.C.)	
371., for MACROPHAGE ACTIVATION)	
INHIBITOR)	

MAIL STOP PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§1.56 and 1.97(b), applicants bring to the Examiner's attention the documents listed on attached Form PTO/SB/08 and cited in the international search report. Copies of the listed documents are attached. Applicants respectfully request that the Examiner consider the documents listed on attached Form PTO/SB/08 and indicate that they were considered by making an appropriate notation on this form. This Information Disclosure Statement is being filed with the above-referenced application.

The following are listed on the accompanying PTO/SB/08 and are in a non-English language:

1. Japanese Patent Publication No. 2001-352986 - An English language translation of this document is enclosed.
2. WIPO Publication No. WO 01/12588 A1 - An English language abstract of this document is enclosed.

In lieu of a statement of relevance or the translation of the non-English documents, also enclosed is an English-language international search report from the Japanese Patent Office in the PCT international application, from which this national phase U.S. application is derived, citing these documents and setting forth the relevance thereof.


This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents. Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: February 6, 2006

By:  20,338
David W. Hill
Reg. No. 28,220

Enclosures
DWH/FPD/sci

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	Not Yet Assigned
				Filing Date	February 6, 2006
				First Named Inventor	Kazuo UMEZAWA et al.
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	09707.0007

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-			
		US-			

Note: Copies of the U.S. Patent Documents are not Required in IDS filed after October 21, 2004

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		JP 2001-352986	12-25-2001	OBATA et al.		YES
		WO 01/12588 A1	02-22-2001	TAKEUCHI et al.		ABSTRACT

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶
		MATSUMOTO, N. et al., "Synthesis of NF-kB Activation Inhibitors Derived from Epoxyquinomicin C," Bioorganic & Medicinal Chemistry Letters, Vol. 10, pp. 865-869, (2000).	
		LIN, Y. L. et al., "(-)-Epigallocatechin-3-Gallate Blocks the Induction of Nitric Oxide Synthase by Down-Regulating Lipopolysaccharide-Induced Activity of Transcription of Factor Nuclear Factor-kB," Molecular Pharmacology, Vol. 52, pp. 465-472, (1997).	
		OHLSSON, B. G. et al., "Oxidized Low Density Lipoprotein Inhibits Lipopolysaccharide-Induced Binding of Nuclear Factor-kB to DNA and the Subsequent Expression of Tumor Necrosis Factor-α and Interleukin-1β in Macrophages," Journal of Clinical Investigation, Vol. 98, No. 1, pp. 78-89, (1996).	
		ELIGINI, S. et al., "Oxidized Phospholipids Inhibit Cyclooxygenase-2 in Human Macrophages Via Nuclear Factor-kB/IkB- and ERK2-Dependent Mechanism," Cardiovascular Research, Vol. 55, pp. 406-415, (2002).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.